A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function

American Journal of Respiratory Cell and Molecular Biology

Volumn 51, Issue 3, 2014, Pages 354-362

  Ramachandran, Shyam ^a   Osterhaus, Samantha R ^a   Karp, Philip H ^a   Welsh, Michael J ^a   McCray Jr , Paul B ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Airway epithelia; Connectivity map; Corrector compound 18; Cystic fibrosis; Small molecule compound

Indexed keywords

ANION CHANNEL; BIPERIDEN; CFTR CORRECTOR COMPOUND 18; CHLORIDE CHANNEL AFFECTING AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; MICRORNA; MICRORNA 138; MIDODRINE; NEOSTIGMINE; PIZOTIFEN; PYRIDOSTIGMINE; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; BIOGENESIS; BIOSYNTHESIS; CELL MATURATION; CELL MIGRATION; CHLORIDE CURRENT; CONFORMATIONAL TRANSITION; CONNECTOME; COOPERATION; CYSTIC FIBROSIS; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENOMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN DEGRADATION; PROTEIN FUNCTION; RESPIRATORY EPITHELIUM;

AIRWAY EPITHELIA; CONNECTIVITY MAP; CORRECTOR COMPOUND 18; CYSTIC FIBROSIS; SMALL MOLECULE COMPOUND;

BIPERIDEN; BRONCHI; CHLORIDES; COMPUTATIONAL BIOLOGY; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE EXPRESSION REGULATION; GENOME, HUMAN; GENOMICS; HELA CELLS; HUMANS; PHENOTYPE; PIZOTYLINE; PROTEIN TRANSPORT; PYRIDOSTIGMINE BROMIDE; RESPIRATORY MUCOSA; SOFTWARE; VALPROIC ACID;

EID: 85047689539     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0007OC     Document Type: Article

References (47)

1. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992;358:761-764.
2. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996;1:117-125. (Pubitemid 126670773)
3. Okiyoneda T, Barriere H, Bagdany M, Rabeh WM, Du K, Hohfeld J, Young JC, Lukacs GL. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 2010;329:805-810.
4. Ott CJ, Bischof JM, Unti KM, Gillen AE, Leir SH, Harris A. Nucleosome occupancy reveals regulatory elements of the CFTR promoter. Nucleic Acids Res 2012;40:625-637.
5. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005;115:2564-2571. (Pubitemid 41266219)
6. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011;108:18843-18848.
7. Sondo E, Tomati V, Caci E, Esposito AI, Pfeffer U, Pedemonte N, Galietta LJ. Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am J Physiol Cell Physiol 2011;301:C872-C885.
8. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363:1991-2003.
9. Ramachandran S, Karp PH, Jiang P, Ostedgaard LS, Walz AE, Fisher JT, Keshavjee S, Lennox KA, Jacobi AM, Rose SD, et al. A microRNA network regulates expression and biosynthesis of wildtype and DeltaF508 mutant cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA 2012;109:13362- 13367.
10. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-1935. (Pubitemid 44497995)
11. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008;26:4078-4085.
12. Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, et al. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA 2008;105:19432-19437.
13. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andren O, Johnson LA, et al. Estrogendependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008;100:815-825. (Pubitemid 351809667)
14. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, et al. Gene expression-based chemical genomics identi fies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006;10:331-342. (Pubitemid 44512194)
15. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006;10:321-330. (Pubitemid 44512193)
16. Chen MH, Lin KJ, Yang WL, Kao YW, Chen TW, Chao SC, Chang PM, Liu CY, Tzeng CH, Chao Y, et al. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer 2013;119:293-303.
17. Edris B, Fletcher JA, West RB, van de Rijn M, Beck AH. Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma. Sarcoma 2012;2012:805614.
18. Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, Suzuki M, Gosselink JV, Liu G, Alekseyev YO, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med 2012;4:67.
19. Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox DK, Malmberg SE, Alipour F, Shields RK, Adams CM. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 2011;13:627-638.
20. Lamb J, Lu X, Peck D, Wrobel M, Subramanian S, Blat I, Modell J, Lerner J, Liu E, Crawford E, et al.; the MSigDB curation team, the Genetic Analysis Platform. The Broad Institute. Cambridge, MA: The Broad Institute of MIT and Harvard; 2006. Available from: http://www.broadinstitute.org/cmap/
21. Sharma M, Benharouga M, Hu W, Lukacs GL. Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in postendoplasmic reticulum compartments. J Biol Chem 2001;276:8942-8950.
22. Kunzelmann K, Schwiebert EM, Zeitlin PL, Kuo WL, Stanton BA, Gruenert DC. An immortalized cystic fibrosis tracheal epithelial cell line homozygous for the delta F508 CFTR mutation. Am J Respir Cell Mol Biol 1993;8:522-529.
23. Lim M, McKenzie K, Floyd AD, Kwon E, Zeitlin PL. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol 2004;31:351-357. (Pubitemid 39180306)
24. Pedemonte N, Galietta LJ. Pharmacological correctors of mutant CFTR mistrafficking. Front Pharmacol 2012;3:175.
25. Thibodeau PH, Richardson JM III, Wang W, Millen L, Watson J, Mendoza JL, Du K, Fischman S, Senderowitz H, Lukacs GL, et al. The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem 2010;285:35825-35835.
26. Galietta LJ. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors. Paediatr Drugs 2013;15:393-402.
27. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A, Verkman AS, Kurth M, Simon A, et al. Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. Nat Chem Biol 2013;9:444-454.
28. Kalid O, Mense M, Fischman S, Shitrit A, Bihler H, Ben-Zeev E, Schutz N, Pedemonte N, Thomas PJ, Bridges RJ, et al . Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des 2010;24:971-991.
29. Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, Hoch B, Kellner W, Kelly JW, Schmidt A, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010;6:25-33.
30. Holleran JP, Glover ML, Peters KW, Bertrand CA, Watkins SC, Jarvik JW, Frizzell RA. Pharmacological rescue of mutant CFTR detected using a novel fluorescence platform. Mol Med 2012;18:685-696.
31. Phuan PW, Yang B, Knapp JM, Wood AB, Lukacs GL, Kurth MJ, Verkman AS. Cyanoquinolines with independent corrector and potentiator activities restore DeltaPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. Mol Pharmacol 2011;80:683-693.
32. Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006;127:803-815. (Pubitemid 44716255)
33. Zhang D, Ciciriello F, Anjos SM, Carissimo A, Liao J, Carlile GW, Balghi H, Robert R, Luini A, Hanrahan JW, et al. Ouabain mimics low temperature rescue of F508del-CFTR in cystic fibrosis epithelial cells. Front Pharmacol 2012;3:176.
34. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-18.
35. Moschos SA, Frick M, Taylor B, Turnpenny P, Graves H, Spink KG, Brady K, Lamb D, Collins D, Rockel TD, et al. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol Ther 2011;19:2163-2168.
36. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011;12:329-340.
37. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-730. (Pubitemid 37361545)
38. ClinicalTrials.gov results database. Study of VX-809 alone and in combination with VX-770 in cystic fibrosis (CF) patients homozygous or heterozygous for the F508del-CFTR mutation. ClinicalTrials.gov Identifier: NCT01225211. National Library of Medicine (NLM) at the National Institutes of Health (NIH); 2010 [updated 2014 Feb 27]. Available from: http://www. clinicaltrials.gov/
39. Wright JM, Zeitlin PL, Cebotaru L, Guggino SE, Guggino WB. Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heatshock proteins. Physiol Genomics 2004;16:204-211. (Pubitemid 38420037)
40. Wang Y, Loo TW, Bartlett MC, Clarke DM. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem J 2007;406:257-263. (Pubitemid 47310956)
41. He L, Kota P, Aleksandrov AA, Cui L, Jensen T, Dokholyan NV, Riordan JR. Correctors of DeltaF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J 2013;27:536-545.
42. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, et al. Predicting new molecular targets for known drugs. Nature 2009;462:175-181.
43. Plewczynski D, Rychlewski L. Meta-basic estimates the size of druggable human genome. J Mol Model 2009;15:695-699.
44. Engreitz JM, Chen R, Morgan AA, Dudley JT, Mallelwar R, Butte AJ. ProfileChaser: searching microarray repositories based on genome-wide patterns of differential expression. Bioinformatics 2011;27:3317-3318.
45. Chen R, Mallelwar R, Thosar A, Venkatasubrahmanyam S, Butte AJ. GeneChaser: identifying all biological and clinical conditions in which genes of interest are differentially expressed. BMC Bioinformatics 2008;9:548.
46. Kodama K, Horikoshi M, Toda K, Yamada S, Hara K, Irie J, Sirota M, Morgan AA, Chen R, Ohtsu H, et al. Expression-based genomewide association study links the receptor CD44 in adipose tissue with type 2 diabetes. Proc Natl Acad Sci USA 2012;109:7049-7054.
47. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, Morgan AA, Sarwal MM, Pasricha PJ, Butte AJ. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011;17:93-96.